ATE260912T1 - Oxazol ppar antagonisten - Google Patents
Oxazol ppar antagonistenInfo
- Publication number
- ATE260912T1 ATE260912T1 AT00959913T AT00959913T ATE260912T1 AT E260912 T1 ATE260912 T1 AT E260912T1 AT 00959913 T AT00959913 T AT 00959913T AT 00959913 T AT00959913 T AT 00959913T AT E260912 T1 ATE260912 T1 AT E260912T1
- Authority
- AT
- Austria
- Prior art keywords
- agonist
- lxr
- propyl
- ppar
- formula
- Prior art date
Links
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title abstract 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 4
- 102100038495 Bile acid receptor Human genes 0.000 abstract 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 abstract 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 2
- 101150095442 Nr1h2 gene Proteins 0.000 abstract 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 2
- 102000004311 liver X receptors Human genes 0.000 abstract 2
- 108090000865 liver X receptors Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 2
- 102000000536 PPAR gamma Human genes 0.000 abstract 1
- 108010016731 PPAR gamma Proteins 0.000 abstract 1
- 229940125388 beta agonist Drugs 0.000 abstract 1
- 239000002876 beta blocker Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 238000007385 chemical modification Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 238000009510 drug design Methods 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15276199P | 1999-09-08 | 1999-09-08 | |
| US19996900P | 2000-04-27 | 2000-04-27 | |
| PCT/US2000/024364 WO2001017994A1 (en) | 1999-09-08 | 2000-09-01 | Oxazole ppar antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE260912T1 true ATE260912T1 (de) | 2004-03-15 |
Family
ID=26849844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00959913T ATE260912T1 (de) | 1999-09-08 | 2000-09-01 | Oxazol ppar antagonisten |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6506781B1 (de) |
| EP (1) | EP1210345B1 (de) |
| JP (1) | JP2003508529A (de) |
| AT (1) | ATE260912T1 (de) |
| AU (1) | AU7115300A (de) |
| DE (1) | DE60008763T2 (de) |
| ES (1) | ES2215719T3 (de) |
| WO (1) | WO2001017994A1 (de) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| GB0101933D0 (en) * | 2001-01-25 | 2001-03-07 | Astrazeneca Ab | Therapy |
| SI1413331T1 (sl) | 2001-01-26 | 2008-02-29 | Schering Corp | Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije |
| EP1911462A3 (de) | 2001-01-26 | 2011-11-30 | Schering Corporation | Zusammensetzungen enthaltend einen Sterolabsorptionshemmer |
| JP4711600B2 (ja) | 2001-01-26 | 2011-06-29 | シェーリング コーポレイション | シトステロール血症の処置のための置換アゼチジノン化合物の使用 |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| WO2002076959A1 (en) * | 2001-03-23 | 2002-10-03 | Takeda Chemical Industries, Ltd. | Five-membered heterocyclic alkanoic acid derivative |
| ATE480236T1 (de) * | 2001-04-25 | 2010-09-15 | Takeda Pharmaceutical | Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans |
| US20030092736A1 (en) * | 2001-05-30 | 2003-05-15 | Cheng Peter T. | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| US6967212B2 (en) * | 2001-05-30 | 2005-11-22 | Bristol-Myers Squibb Company | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| KR20040044515A (ko) * | 2001-08-29 | 2004-05-28 | 워너-램버트 캄파니 엘엘씨 | 경구용 항당뇨병제 |
| US6869975B2 (en) | 2001-09-14 | 2005-03-22 | Tularik Inc. | Linked biaryl compounds |
| US7132415B2 (en) | 2001-09-21 | 2006-11-07 | Schering Corporation | Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| GB2381866A (en) * | 2001-11-12 | 2003-05-14 | Karobio Ab | Assays for liver X receptor (LXR) modulators |
| WO2003043997A1 (en) * | 2001-11-15 | 2003-05-30 | Eli Lilly And Company | Peroxisome proliferator activated receptor alpha agonists |
| EP1465882B1 (de) | 2001-12-21 | 2011-08-24 | X-Ceptor Therapeutics, Inc. | Heterocyclische modulatoren von nukleären rezeptoren |
| US6870466B2 (en) * | 2002-04-03 | 2005-03-22 | Hewlett-Packard Development Company, L.P. | Data display system and method for an object traversing a circuit |
| US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
| US6790929B2 (en) | 2002-06-12 | 2004-09-14 | General Electric Company | Method for making an aromatic polycarbonate |
| MXPA05000279A (es) * | 2002-07-09 | 2005-03-31 | Squibb Bristol Myers Co | Derivados heterociclicos sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo. |
| US7137963B2 (en) * | 2002-08-26 | 2006-11-21 | Flowcardia, Inc. | Ultrasound catheter for disrupting blood vessel obstructions |
| WO2004024705A1 (ja) | 2002-09-10 | 2004-03-25 | Takeda Pharmaceutical Company Limited | ５員複素環化合物 |
| CA2504878A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorption inhibitors for the treatment of demyelination |
| JP2007504285A (ja) * | 2003-01-17 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | Ｎ−シクロヘキシルアミノカルボニルベンゼンスルホンアミド誘導体 |
| CA2513157A1 (en) * | 2003-01-22 | 2004-08-12 | Merck & Co., Inc. | Peroxisome proliferator-activated receptor |
| DE10308353A1 (de) * | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CN1756755A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| JP4589919B2 (ja) | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
| CN100439361C (zh) | 2003-03-07 | 2008-12-03 | 先灵公司 | 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| US6987118B2 (en) | 2003-05-21 | 2006-01-17 | Pfizer Inc. | Tetrahydroisoquinoline derivatives as PPAR-alpha activators |
| RU2365589C2 (ru) * | 2004-04-01 | 2009-08-27 | Авентис Фармасьютикалз Инк. | 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта, фармацевтические композиции на их основе и способ лечения |
| DE602005027677D1 (de) | 2004-04-01 | 2011-06-09 | Aventis Pharma Inc | 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung |
| CN100436430C (zh) * | 2004-05-24 | 2008-11-26 | 北京摩力克科技有限公司 | 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物 |
| CN100467456C (zh) * | 2004-05-24 | 2009-03-11 | 北京摩力克科技有限公司 | 作为hPPARα和/或hPPARγ激活剂的α-哌嗪取代的苯丙酸衍生物 |
| CA2576993C (en) * | 2004-08-12 | 2013-09-24 | Amgen Inc. | Bisaryl-sulfonamides |
| US20070142326A1 (en) * | 2004-09-30 | 2007-06-21 | Youe-Kong Shue | Treatment of a condition in a mammal with administration of aminosugar and uses thereof |
| US20100055066A1 (en) * | 2004-10-15 | 2010-03-04 | Kazuo Suzuki | Agent for prophylactic and/or therapeutic treatment of diabetes |
| WO2006044961A1 (en) * | 2004-10-20 | 2006-04-27 | Smithkline Beecham Corporation | Ppar-gamma modulatores |
| PL371841A1 (pl) | 2004-12-20 | 2006-06-26 | ADAMED Sp.z o.o. | Nowe związki pochodne kwasu 3-fenylopropionowego |
| PL372332A1 (pl) | 2005-01-19 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
| PL372356A1 (pl) | 2005-01-20 | 2006-07-24 | ADAMED Sp.z o.o. | Nowe związki, pochodne kwasu 3-fenylopropionowego |
| WO2006094014A2 (en) | 2005-02-28 | 2006-09-08 | The Regents Of The University Of California | Methods for diagnosis and treatment of endometrial cancer |
| WO2006113526A2 (en) | 2005-04-15 | 2006-10-26 | The Regents Of The University Of California | Prevention of chlamydia infection using a protective antibody |
| US8648052B2 (en) * | 2005-04-15 | 2014-02-11 | The Regents Of The University Of California | Prevention of chlamydia infection using SIRNA |
| US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| EP2501409A4 (de) | 2009-11-20 | 2015-02-18 | Univ California | Epithelialmembranenprotein-2 (emp2) und proliferative vitreoretinopathie (pvr) |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| JP6366721B2 (ja) | 2013-09-11 | 2018-08-01 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｂ型肝炎ウイルス感染症を処置するための方法及び医薬組成物 |
| US20160199364A1 (en) * | 2015-01-13 | 2016-07-14 | Creighton University | Seizure treatment compositions and methods |
| CN106146483A (zh) * | 2015-04-23 | 2016-11-23 | 上海迪诺医药科技有限公司 | 杂环类法尼酯衍生物x受体调节剂 |
| EP3600293A1 (de) | 2017-03-30 | 2020-02-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Verfahren und pharmazeutische zusammensetzungen zur reduzierung und expression von episomalen viren |
-
2000
- 2000-09-01 AT AT00959913T patent/ATE260912T1/de not_active IP Right Cessation
- 2000-09-01 DE DE60008763T patent/DE60008763T2/de not_active Expired - Fee Related
- 2000-09-01 WO PCT/US2000/024364 patent/WO2001017994A1/en not_active Ceased
- 2000-09-01 EP EP00959913A patent/EP1210345B1/de not_active Expired - Lifetime
- 2000-09-01 JP JP2001522217A patent/JP2003508529A/ja not_active Withdrawn
- 2000-09-01 ES ES00959913T patent/ES2215719T3/es not_active Expired - Lifetime
- 2000-09-01 US US10/070,474 patent/US6506781B1/en not_active Expired - Fee Related
- 2000-09-01 AU AU71153/00A patent/AU7115300A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60008763T2 (de) | 2005-02-10 |
| AU7115300A (en) | 2001-04-10 |
| US6506781B1 (en) | 2003-01-14 |
| EP1210345A1 (de) | 2002-06-05 |
| DE60008763D1 (de) | 2004-04-08 |
| WO2001017994A1 (en) | 2001-03-15 |
| ES2215719T3 (es) | 2004-10-16 |
| JP2003508529A (ja) | 2003-03-04 |
| EP1210345B1 (de) | 2004-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE260912T1 (de) | Oxazol ppar antagonisten | |
| DK1173433T3 (da) | Cyanopyrroler som progesteronreceptoragonister | |
| HUP0303339A2 (hu) | Heteroaril-karbamid neuropeptid Y Y5 receptor antagonisták, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| ATE401066T1 (de) | Methoden zur behandlung der essstörungen | |
| NO20003671L (no) | 4-(2-keto-1-benzimidazolinyl)piperidin-forbindelser som orl1- reseptor agonister | |
| MY141559A (en) | Triazole derivatives as tachykinin receptor antagonists | |
| JP2004532209A5 (de) | ||
| CO5611063A2 (es) | Pirazolilcarboxanilidas disubstituidas | |
| DE60120748D1 (de) | 3-substituierte oxindolderivate als beta-3-agonisten | |
| ATE213738T1 (de) | Azaheterocyclische tachykinin rezeptor antagoniste; nk1 und nk2 | |
| IL177252A0 (en) | A method for detecting events on cellular comm network | |
| RU2007121850A (ru) | Производные фосфонооксихиназолина и их фармацевтическое применение | |
| BR9508292A (pt) | Processos para a sintese enãncio-seletiva de um composto,(-)-5-metóxi-2[[(4-metóxi-3,5-dimetil-2-piridinil) metil]sulfinil]-1h-benzimidazol,(+)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-fluoro-2-(((4-ciclopropilmetóxi-2-piridinil) metil) sulfinil)-1h-benzimidazol,(-)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h-benzimidazol,(+)-5-carbometóxi-6-metil-2-[[(3,4-dimetóxi-2-piridinil) metil] sulfinil]-1h benzimidazol composto e uso dos compostos | |
| DE60218703D1 (de) | (-)-1-(3,4-dichlorphenyl)-3-azabicyclo ä3.1.0ühexan, zusammensetzungen davon und verwendung als dopamin-wiederaufnahme-hemmer | |
| MY146532A (en) | Thiazole derivative | |
| UA72917C2 (en) | Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor | |
| ATE256670T1 (de) | Isoxazolcarboxamid-derivate als antagonisten des alpha1-adrenergischen rezeptors | |
| PE20011212A1 (es) | Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica | |
| NO992226D0 (no) | Nye forbindelser for anvendelse som neuro-protektive midler | |
| DK1487424T3 (da) | 4-(4-Methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyridin-3-yl)-pyrimidin-2-yl-amino)phenyl-benzamid til behandling af Ang II-medierede sygdomme | |
| NO20014855D0 (no) | N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister | |
| ATE366572T1 (de) | 5-ht 1b/1d rezeptor agonisten zur behandlung von kopfschmerz der aus der verabreichung von endothelin rezeptor antagonisten resultiert | |
| NO20042257L (no) | Fremgangsmate for behandling av depresjon med deltareseptoragonistforbindelser | |
| PE20060770A1 (es) | Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1 | |
| DK0925295T3 (da) | Derivater af N-benzensulfonyl-L-prolin som antagonister af receptoren B2 for bradykinin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |